5 FLUOROURACIL & LEUCOVORIN IN CANCER PATIENTS WITH RENAL OR HEPATIC DYSFUNCTION

5氟尿嘧啶

• 批准号: 6245560
• 负责人: GINI F. FLEMING
• 金额: $ 3.72万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245560
• 关键词: bilirubin; circadian rhythms; clinical research; combination chemotherapy; creatine; dosage; fluorouracil; human subject; human therapy evaluation; kidney disorder; kidney function; leucovorin; liver disorder; liver function; neoplasm /cancer chemotherapy; pharmacokinetics

A 24 hour infusion of 5-FU and leucovorin will be administered to cancer patients with an elevated bilirubin or an elevated creatinine, and the maximum tolerated dose(s) of the combination will be established. Plasma levels of 5-FU will be obtained for pharmacodynamic analysis and to study the circadian variation of 5-FU levels during a constant-rate infusion.

癌症患者将接受24小时输注5-FU和甲酰四氢叶酸 胆红素升高或肌酐升高的患者， 将确定组合的最大耐受剂量。 血浆 将获得5-FU水平，用于药效学分析和研究 恒速输注期间5-FU水平的昼夜变化。